Patients with adenocarcinoma of the stomach or GE junction treated with tesetaxel, a novel, orally absorbed taxane, had median overall survival (OS) rates of 7.6 and 7.5 months, according to a phase 2b trial.
Debra Hughes, MS
Debra (Lumpe) Hughes has more than 3 decades of oncology medical writing and editing experience, including as a former editor of Oncology Times. She has a diverse background in medical journalism, education, and publishing. Her company, D.A. Hughes & Associates, provides medical communications services for academic institutions, communications and publishing companies, global pharmaceutical and biotechnology corporations, and professional medical associations and societies. Debra is an alumna of Columbia University Graduate School of Journalism, where she specialized in science writing, and the University of California, Riverside.